logo
  

ANI Pharma Q4 Adj. Profit Declines

ANI Pharmaceuticals, Inc. (ANIP) reported fourth quarter adjusted non-GAAP earnings per share of $0.54, compared to $0.80, a year ago. On average, three analysts polled by Thomson Reuters expected the company to report profit per share of $0.74, for the quarter. Analysts' estimates typically exclude special items. Adjusted non-GAAP EBITDA was $16.2 million compared to $17.2 million.

Net loss for the fourth quarter of 2021 was $24.1 million as compared to a net loss of $3.6 million, prior year. Loss per share was $1.72, compared to a loss per share of $0.30.

Net revenues were $60.9 million compared to $57.3 million, a year ago. Analysts on average had estimated $56.3 million in revenue.

Net revenues for generic pharmaceutical products were $41.6 million during the three months ended December 31, 2021, an increase of 8% compared to $38.7 million for the same period in 2020. Net revenues for branded pharmaceutical products were $14.7 million during the three months ended December 31, 2021, a decrease of 7% compared to $15.8 million for the same period in 2020.

Cash and cash equivalents were $100.3 million, net accounts receivable was $128.5 million, and face value of debt was $300.0 million as of December 31, 2021.

For fiscal 2022, total company ex-Purified Cortrophin Gel measures, net revenues are projected to be between $260.0 million and $275.0 million, representing approximately 20% to 27% growth as compared to 2021. Adjusted non-GAAP EBITDA is estimated between $70.0 million and $75.0 million, representing 8% to 16% growth as compared to 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. air travel industry is going through its worst crisis since the troubled travel time during the peek pandemic struggles, with thousands of flights across the country being cancelled or getting delayed. The aviation crisis, as millions are preparing to travel during the upcoming July 4th holiday weekend, is mainly attributed to the staffing issues at airlines, ... The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for Siluriformes products imported by Carlstadt, New Jersey- based Grand BK Corp. The products were imported from Korea, a country ineligible to export Siluriformes products to the United States. Blount Fine Foods is recalling a limited amount of Panera at Home Southwest Corn Chowder citing undeclared wheat allergen, the U.S. Food and Drug Administration said. The recall involves a single lot of 16 oz. product with UPC Code 077958690812, lot number 042122-2K and "Use By" date of 6/30/22 that comes around 2,569 cases in total. The recall is limited to 1 SKU of 16 oz.
Follow RTT